期刊文献+

Research Highlight in Stroke

Research Highlight in Stroke
下载PDF
导出
摘要 Abstract:Stroke is currently the second leading cause of mortality and adult disability in the world.It expects to increase dramatically over the coming years.Stroke and its related illnesses cost the healthcare system billions of dollars each year worldwide,thus causing significant financial burden and economic hardship in the world.The disabilities afflicted in stroke survivors have also created significant social and economic impacts on societies worldwide.It is thus imperative that medical researchers develop effective treatment strategies in order to meet this today's challenge.Presently,even the cellular and molecular mechanisms of stroke are better understood,the effective treatment for stroke is still very limited.This has led stroke researchers to pursue different neuroprotective strategies aiming non-glutamate mechanisms to prevent neuronal damage and to promote neuronal survival,regeneration and functional recovery in stroke,thus offering potentially long-term economic,social,and healthcare benefits worldwide. Stroke is currently the second leading cause of mortality and adult disability in the world. It expects to increase dramatically over the coming years. Stroke and its related illnesses cost the healthcare system billions of dollars each year worldwide, thus causing significant financial burden and economic hardship in the world. The disabilities afflicted in stroke survivors have also created significant social and economic impacts on societies worldwide. It is thus imperative that medical researchers develop effective treatment strategies in order to meet this today's challenge. Presently, even the cellular and molecular mechanisms of stroke are better understood, the effective treatment for stroke is still very limited. This has led stroke researchers to pursue different neuroprotective strategies aiming non-glutamate mechanisms to prevent neuronal damage and to promote neuronal survival, regeneration and funetional recovery in stroke, thus offering potentially long-term economic, social, and healthcare benefits worldwide.
作者 孙宏硕
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2014年第1期8-11,共4页 Journal of Sun Yat-Sen University:Medical Sciences
基金 2013年度国家自然科学基金委员会(NSFS)与加拿大卫生研究院(CIHR)健康研究合作计划项目 加拿大自然科学和工程研究基金会基金
关键词 脑卒中 中风 治疗方法 临床分析 stroke treatment strategies non-glutamate mechanisms neuronal survival regeneration functional recovery
  • 相关文献

参考文献10

  • 1Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2012 update:a report from the American Heart Association[J]. Circulation, 2012, 125(9) : e2-220.
  • 2O'Collins VE, Macleod MR, Donnan GA, et al. 1,026 Experimental treatments in acute stroke [J]. Ann Neurol, 2006, 59(9): 467-477.
  • 3Hill MD, Martin RH, Mikulis D, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT) : a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol, 2012, 11(9): 942-950.
  • 4Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? [J], Lancet Neurol, 2002, 1(9): 383- 386.
  • 5Sattler R, Xiong Z, Lu WY, et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein [ J ]. Science, 1999,284 (9) : 1845-1848.
  • 6Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions [ J ]. Science, 2002, 298 (9) : 846- 850.
  • 7Sun HS, Doucette TA, Liu Y, et al. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat[J~. Stroke, 2008, 39(9): 2544- 2453.
  • 8Bratane BT, Cui H, Cook D J, et al. Neuroprotection by freezing ischemie penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor [J]. Stroke, 2011, 42 (8) : 3265- 3270.
  • 9Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalie primate brainIJ]. Nature, 2012, 483(8): 213-218.
  • 10Cook DJ, Teves L, Tymianski M. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates[J]. Sci Transl Med, 2012, 4(8) : 1-8.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部